参考文献/References:
[1].Panza JA,Chrzanowski L,Bonow RO. Myocardial viability assessment before surgical revascularization in ischemic cardiomyopathy:JACC review topic of the week[J]. J Am Coll Cardiol,2021,78(10):1068-1077.
[2].Knuuti J,Wijns W,Saraste A,et al. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes[J]. Eur Heart J,2020,41(3):407-477.
[3].Neumann FJ,Sousa-Uva M,Ahlsson A,et al. 2018 ESC/EACTS Guidelines on myocardial revascularization[J]. Eur Heart J,2019,40(2):87-165.
[4].中华医学会核医学分会,中华医学会心血管病学分会. 核素心肌显像临床应用指南(2018)[J]. 中华心血管病杂志,2019,47(7):519-527.
[5].Patel P,Ivanov A,Ramasubbu K. Myocardial viability and revascularization:current understanding and future directions[J]. Curr Atheroscler Rep,2016,18(6):32.
[6].McDiarmid AK,Pellicori P,Cleland JG,et al. Taxonomy of segmental myocardial systolic dysfunction[J]. Eur Heart J,2017,38(13):942-954.
[7].Ker WDS,Nunes THP,Nacif MS,et al. Practical implications of myocardial viability studies[J]. Arq Bras Cardiol,2018,110(3):278-288.
[8].Madsen S,Dias AH,Lauritsen KM,et al. Myocardial viability testing by positron emission tomography:basic concepts,mini-review of the literature and experience from a tertiary PET center[J]. Semin Nucl Med,2020,50(3):248-259.
[9].Kalogeropoulos AP,Fonarow GC,Georgiopoulou V,et al. Characteristics and outcomes of adult outpatients with heart failure and improved or recovered ejection fraction[J]. JAMA Cardiol,2016, 1(5):510-518.
[10].Namdar M,Rager O,Priamo J,et al. Prognostic value of revascularising viable myocardium in elderly patients with stable coronary artery disease and left ventricular dysfunction:a PET/CT study[J]. Int J Cardiovasc Imaging,2018,34(10):1673-1678.
[11].Slart RH,Bax JJ,van Veldhuisen DJ,et al. Prediction of functional recovery after revascularization in patients with chronic ischaemic left ventricular dysfunction:head-to-head comparison between 99mTc-sestamibi/18F-FDG DISA SPECT and 13N-ammonia/ 18F-FDG PET[J].?Eur J Nucl Med Mol Imaging,2006,33(6):716-723.
[12].Bax JJ,Schinkel AF,Boersma E,et al. Extensive left ventricular remodeling does not allow viable myocardium to improve in left ventricular ejection fraction after revascularization and is associated with worse long-term prognosis[J]. Circulation,2004,110(11 suppl 1):Ⅱ18-Ⅱ22.
[13].Schwarz ER,Schoendube FA,Kostin S,et al. Prolonged myocardial hibernation exacerbates cardiomyocyte degeneration and impairs recovery of function after revascularization[J]. J Am Coll Cardiol,1998,31(5):1018-1026.
[14].vom Dahl J,Altehoefer C,Sheehan FH,et al. Effect of myocardial viability assessed by technetium-99m-sestamibi SPECT and fluorine-18-FDG PET on clinical outcome in coronary artery disease[J].?J Nucl Med,1997,38(5):742-748.
[15].di Carli MF,Asgarzadie F,Schelberet al. Quantitative relation between myocardial viability and improvement in heart failure symptoms after revascularization in patients with ischemic cardiomyopathy[J]. Circulation,1995,92(12):3436-3444.
[16].Allman KC,Shaw LJ,Hachamovitch R,et al. Myocardial viability testing and impact of revascularization on prognosis in patients with coronary artery disease and left ventricular dysfunction:a meta-analysis[J]. J Am Coll Cardiol,2002,39(7):1151-1158.
[17].Desideri A,Cortigiani L,Christen AI,et al. The extent of perfusion-F18-fluorodeoxyglucose positron emission tomography mismatch determines mortality in medically treated patients with chronic ischemic left ventricular dysfunction[J]. J Am Coll Cardiol,2005,46(7):1264-1269.
[18].Ling LF,Marwick TH,Flores DR,et al. Identification of therapeutic benefit from revascularization in patients with left ventricular systolic dysfunction:inducible ischemia versus hibernating myocardium[J]. Circ Cardiovasc Imaging,2013,6(3):363-372.
[19].D’Egidio G,Nichol G,Williams KA,et al. Increasing benefit from revascularization is associated with increasing amounts of myocardial hibernation:a substudy of the PARR-2 trial[J]. JACC Cardiovasc Imaging,2009,2(9):1060-1068.
[20].Liu Y,Jiang Y,Yang X,et al. Limited prognostic value of myocardial viability assessment in patients with coronary artery diseases and severe left ventricular dysfunction[J]. J Thorac Dis,2018,10(4):2249-2255.
[21].Uebleis C,Hellweger S,Laubender RP,et al. The amount of dysfunctional but viable myocardium predicts long-term survival in patients with ischemic cardiomyopathy and left ventricular dysfunction[J].?Int J Cardiovasc Imaging,2013,29(7):1645-1653.
[22].Beanlands RS,Nichol G,Huszti E,et al. F-18-fluorodeoxyglucose positron emission tomography imaging-assisted management of patients with severe left ventricular dysfunction and suspected coronary disease:a randomized,controlled trial(PARR-2)[J]. J Am Coll Cardiol,2007,50(20):2002-2012.
[23].Mc Ardle B,Shukla T,Nichol G,et al. Long-term follow-up of outcomes with F-18-fluorodeoxyglucose positron emission tomography imaging-assisted management of patients with severe left ventricular dysfunction secondary to coronary disease[J]. Circ Cardiovasc Imaging,2016,9(9):e004331.
[24].Abraham A,Nichol G,Williams KA,et al. 18F-FDG PET imaging of myocardial viability in an experienced center with access to 18F-FDG and integration with clinical management teams:the Ottawa-FIVE substudy of the PARR 2 trial[J]. J Nucl Med,2010,51(4):567-574.
[25].Bonow RO,Maurer G,Lee KL,et al. Myocardial viability and survival in ischemic left ventricular dysfunction[J]. N Engl J Med,2011,364(17):1617-1625.
[26].Panza JA,Ellis AM,Al-Khalidi HR,et al. Myocardial viability and long-term outcomes in ischemic cardiomyopathy[J]. N Engl J Med,2019,381(8):739-748.
[27].Perry AS,Mann DL,Brown DL. Improvement of ejection fraction and mortality in ischaemic heart failure[J]. Heart,2020,Aug 25:heartjnl-2020-316975. DOI:10.1136/heartjnl-2020-316975. Epub ahead of print.
相似文献/References:
[1]杜钧,佘强.冠心病抗炎治疗的临床研究进展[J].心血管病学进展,2016,(1):32.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.009]
DU Jun,SHE Qiang.Clinical Research Progress of Anti-inflammatory Therapy of Coronary Heart Disease[J].Advances in Cardiovascular Diseases,2016,(1):32.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.009]
[2]努热曼古丽·阿布都克热木,马依彤.重度左心室收缩功能不全的冠心病患者血运重建治疗疗效及预后的评价[J].心血管病学进展,2016,(1):46.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.012]
NUREMANGULI·Abudukeremu,MA Yitong.Evaluation of Efficacy and Prognosis of Revascularization Therapy on Patients
with Coronary Heart Disease and Severe Left Ventricular Systolic Dysfunction[J].Advances in Cardiovascular Diseases,2016,(1):46.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.012]
[3]刘洋,综述,伍贵富,等.增强型体外反搏治疗冠心病的新机制[J].心血管病学进展,2016,(2):185.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.023]
LIU Yang,WU Guifu.New Mechanism of Enhanced External Counterpulsation for
Treatment of Coronary Artery Disease[J].Advances in Cardiovascular Diseases,2016,(1):185.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.023]
[4]杨洋,综述,沈比先,等.心脏核磁共振评估缺血性心脏病的应用价值[J].心血管病学进展,2016,(2):204.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.028]
YANG Yang,SHEN Bixian.Value of Cardiac Magnetic Resonance Assessment of Ischemic Heart Disease[J].Advances in Cardiovascular Diseases,2016,(1):204.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.028]
[5]史敬,综述,马依彤,等.n-3多不饱和脂肪酸对心血管疾病的临床应用[J].心血管病学进展,2016,(3):278.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.016]
SHI Jing,MA Yitong.Effects of n-3 Polyunsaturated Fatty Acids on Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2016,(1):278.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.016]
[6]高柳,袁晋青.重复支架置入术治疗药物洗脱支架再狭窄的研究进展[J].心血管病学进展,2015,(5):555.[doi:10.3969/j.issn.1004-3934.2015.05.008]
GAO Liu,YUAN Jingqing.Progress in Treatment for Drug-eluting Stent Restenosis by
Re-implementation of Stents[J].Advances in Cardiovascular Diseases,2015,(1):555.[doi:10.3969/j.issn.1004-3934.2015.05.008]
[7]邓文政,邓平.MG53蛋白的研究进展[J].心血管病学进展,2015,(5):626.[doi:10.3969/j.issn.1004-3934.2015.05.027]
DENG Wenzheng,DENG Ping.Research Progress of MG53[J].Advances in Cardiovascular Diseases,2015,(1):626.[doi:10.3969/j.issn.1004-3934.2015.05.027]
[8]陈静,李兴德.冠心病患者服药依从性的研究进展[J].心血管病学进展,2015,(6):728.[doi:10.3969/j.issn.1004-3934.2015.06.018]
CHEN Jing,LI Xingde.Advances in Medication Adherence of Patients with Coronary Heart Disease[J].Advances in Cardiovascular Diseases,2015,(1):728.[doi:10.3969/j.issn.1004-3934.2015.06.018]
[9]姚雯,毛露,孙硕,等.心源性外泌体作为冠心病标志物和新靶点展望[J].心血管病学进展,2019,(6):844.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.002]
YAO Wen,MAO Lu,SUN Shuo,et al.Exogenous Exosome as A New Marker and Target of Coronary Heart Disease[J].Advances in Cardiovascular Diseases,2019,(1):844.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.002]
[10]郭彩艳 靳春荣.腺苷药物在心血管疾病诊治中的应用进展[J].心血管病学进展,2019,(7):1011.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.012]
GUO CaiyanJIN Chunrong.Progress in the Application of Adenosine Drugs in the Diagnosis and Treatment of Cardiovascular Diseases[J].Advances in Cardiovascular Diseases,2019,(1):1011.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.012]